(NANCY, France) -- A new French study suggests that regular treatment, including a four-drug chemotherapy combo, can almost double the survival time in patients with fatal pancreatic cancer.
Researchers in the study divided 342 patients with advanced stage pancreatic cancer into two groups, giving one group the standard treatment and the other FOLFIRINOX -- the four-drug combination therapy.
Results published in the New England Journal of Medicine show that the median survival time improved from almost 7 months for patients receiving the traditional treatment, to just over 11 months for patients receiving the combo. Despite the improved survival time, patients in the combo group suffered greater side effects, however.
The study authors conclude that the FOLFIRINOX regimen can stabilize patients for a greater amount of time while delaying degradation of quality of life.
Copyright 2011 ABC News Radio